Banco Santander S.A. Sells 26,647 Shares of Gilead Sciences, Inc. $GILD

Banco Santander S.A. cut its position in Gilead Sciences, Inc. (NASDAQ:GILD) by 16.7% in the second quarter, HoldingsChannel.com reports. The firm owned 133,197 shares of the biopharmaceutical company’s stock after selling 26,647 shares during the period. Banco Santander S.A.’s holdings in Gilead Sciences were worth $14,768,000 as of its most recent SEC filing.

A number of other large investors have also added to or reduced their stakes in the company. Smallwood Wealth Investment Management LLC acquired a new position in shares of Gilead Sciences during the first quarter valued at about $25,000. Activest Wealth Management raised its position in shares of Gilead Sciences by 2,837.5% in the 1st quarter. Activest Wealth Management now owns 235 shares of the biopharmaceutical company’s stock valued at $26,000 after purchasing an additional 227 shares during the last quarter. Harbor Asset Planning Inc. purchased a new position in shares of Gilead Sciences in the 2nd quarter valued at approximately $27,000. Goodman Advisory Group LLC purchased a new position in shares of Gilead Sciences in the 1st quarter valued at approximately $29,000. Finally, Colonial Trust Advisors raised its position in shares of Gilead Sciences by 304.3% in the 1st quarter. Colonial Trust Advisors now owns 283 shares of the biopharmaceutical company’s stock valued at $32,000 after purchasing an additional 213 shares during the last quarter. 83.67% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

Several brokerages recently commented on GILD. Wolfe Research increased their price objective on shares of Gilead Sciences from $135.00 to $140.00 and gave the company an “outperform” rating in a research report on Thursday. Weiss Ratings reaffirmed a “buy (b)” rating on shares of Gilead Sciences in a research report on Saturday. Royal Bank Of Canada increased their price objective on shares of Gilead Sciences from $98.00 to $100.00 and gave the company a “sector perform” rating in a research report on Wednesday, October 8th. Cantor Fitzgerald increased their price objective on shares of Gilead Sciences from $129.00 to $135.00 and gave the company an “overweight” rating in a research report on Thursday, October 9th. Finally, Dbs Bank raised shares of Gilead Sciences to a “moderate buy” rating in a research report on Friday, September 5th. One investment analyst has rated the stock with a Strong Buy rating, twenty have assigned a Buy rating and six have assigned a Hold rating to the company. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $122.61.

Insider Transactions at Gilead Sciences

In other news, CEO Daniel Patrick O’day sold 10,000 shares of the firm’s stock in a transaction that occurred on Monday, September 29th. The shares were sold at an average price of $111.66, for a total transaction of $1,116,600.00. Following the sale, the chief executive officer owned 591,203 shares of the company’s stock, valued at $66,013,726.98. This trade represents a 1.66% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, CFO Andrew D. Dickinson sold 2,500 shares of the firm’s stock in a transaction that occurred on Wednesday, October 15th. The stock was sold at an average price of $118.08, for a total transaction of $295,200.00. Following the sale, the chief financial officer directly owned 157,055 shares in the company, valued at $18,545,054.40. The trade was a 1.57% decrease in their position. The disclosure for this sale can be found here. Insiders have sold 61,500 shares of company stock valued at $7,142,140 in the last 90 days. 0.27% of the stock is currently owned by company insiders.

Gilead Sciences Price Performance

Shares of NASDAQ:GILD opened at $120.94 on Monday. Gilead Sciences, Inc. has a twelve month low of $86.08 and a twelve month high of $124.61. The company’s 50 day moving average is $115.47 and its 200 day moving average is $111.11. The company has a current ratio of 1.32, a quick ratio of 1.15 and a debt-to-equity ratio of 1.13. The company has a market cap of $150.06 billion, a PE ratio of 24.09, a price-to-earnings-growth ratio of 0.83 and a beta of 0.34.

Gilead Sciences (NASDAQ:GILD) last issued its quarterly earnings results on Thursday, August 7th. The biopharmaceutical company reported $2.01 earnings per share for the quarter, topping the consensus estimate of $1.96 by $0.05. Gilead Sciences had a net margin of 21.86% and a return on equity of 50.99%. The company had revenue of $7.08 billion for the quarter, compared to the consensus estimate of $6.95 billion. During the same quarter in the prior year, the company earned $2.01 EPS. Gilead Sciences’s quarterly revenue was up 1.4% on a year-over-year basis. Gilead Sciences has set its FY 2025 guidance at 7.950-8.250 EPS. On average, sell-side analysts forecast that Gilead Sciences, Inc. will post 7.95 EPS for the current year.

Gilead Sciences Announces Dividend

The company also recently disclosed a quarterly dividend, which was paid on Monday, September 29th. Stockholders of record on Monday, September 15th were paid a dividend of $0.79 per share. The ex-dividend date of this dividend was Monday, September 15th. This represents a $3.16 dividend on an annualized basis and a dividend yield of 2.6%. Gilead Sciences’s dividend payout ratio (DPR) is presently 62.95%.

Gilead Sciences Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.